DermaSpan Acellular Dermal Matrix
- Acellular dermal matrix derived from allograft human skin
- One of the few acellular dermal matrix that is irradiated under a validated sterilization process1
- Using sterile graft further reduces the risk of disease donor transmission2
- Dermaspan is supplied sterile (SAL-10-6)
- One lab study has shown acellular dermal matrix leads to reduced chance of inflammatory response3
- Infiltrated by host tissue in animal studies4
- Consistence thickness of allograft6
- No refrigeration required
DermaSpan Acellular Dermal Matrix Strength Properties
Suture failed before graft (Excel 0.0 green braided suture)
166.1 N pull-out strength with stainless steel wire
- Tissue Banks International. Histological investigations of recellularization, revascularization, adhesions and other factors in three animal models of Tissue banks Internationals sterile human acellular dermal allograft. April 27, 2010. Animal studies are not necessarily indicative of clinical performance.
- Richters, C. D., A. Pirayesh, H. Hoeksema, E. W. A. Kamperdijk, R. W. Kreis, R. P. Dutrieux, S. Monstrey, and M. J. Hoekstra. “Development of a Dermal Matrix from Glycerol Preserved Allogeneic Skin.” Cell and Tissue Banking 9.4 (2008): 309-15. Print.
- Jacobsen, Garth, and David Easter. “Allograft vs. Xenograft Practical Considerations for Biologic Scaffolds.” BellaDerm. MTF. Web. 07 Feb. 2011.
- Michael, Trice E. “Xenograft Risks: What You and Your Patients Need to Know.” American Academy of Orthopaedic Surgeons - AAOS. June 2009. Web. 07 Feb. 2011.
- TBI-ACD Mechanical Testing, May 18, 2010
- TBI-ACD Measurement Protocol